FDA-cleared profile

Brainomix 360 e-ASPECTS

Brainomix Limited · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Assists clinician assessment of brain abnormalities and ischemic injury by generating an automated ASPECTS score for known MCA/ICA occlusion cases.

Clinical role
Computer-aided diagnosis software that assists the clinician by providing highlighted ASPECTS regions and an automated editable ASPECTS score from CT image data for clinician review; not intended for primary interpretation of CT images.
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: Not primary CT interpretation; not validated for non-acute-stroke pathologies, hemorrhagic transformation, hematoma, motion-degraded scans, or use outside brain ischemia within 6 hours; intended for patients over 21 and Siemens Somatom Definition scanners; not for mobile diagnostic use.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Assists clinician assessment of brain abnormalities and ischemic injury by generating an automated ASPECTS score for known MCA/ICA occlusion cases.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: NCCT brain data for patients over 21 with known MCA/ICA occlusion, within the labeled ischemia time window.
  • Who uses it?Intended users: Clinicians and physicians, with physician review and verification.
  • What does the software produce?Output: Editable ASPECTS score, highlighted/labelled regions, voxel-inclusion/exclusion heatmaps, affected side, report, and PACS-exportable results.
  • What is its most important limitation?Key limitation: Not primary CT interpretation; not validated for non-acute-stroke pathologies, hemorrhagic transformation, hematoma, motion-degraded scans, or use outside brain ischemia within 6 hours; intended for patients over 21 and Siemens Somatom Definition scanners; not for mobile diagnostic use.

Clinical takeaway. Clinical role: Assists clinician assessment of brain abnormalities and ischemic injury by generating an automated ASPECTS score for known MCA/ICA occlusion cases.

Evidence takeaway. Evidence from the reviewed source record: FDA reports standalone testing on 256 NCCT scans from 8 U.S. institutions: AUC 83% (81-85), sensitivity 68% (57-72), and specificity 97% (86-98); it also reports 200 digital-phantom heatmap testing and a 54-scan/10-reader MRMC study.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Assists clinician assessment of brain abnormalities and ischemic injury by generating an automated ASPECTS score for known MCA/ICA occlusion cases.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.

Workflow role
Computer-aided diagnosis software that assists the clinician by providing highlighted ASPECTS regions and an automated editable ASPECTS score from CT image data for clinician review; not intended for primary interpretation of CT images.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Brainomix 360 e-ASPECTS is a computer-aided diagnosis (CADx) software device used to assist the clinician in the assessment and characterization of brain tissue abnormalities using CT image data." … "Brainomix 360 e-ASPECTS provides a comparative analysis to the ASPECTS standard of care radiologist assessment by providing highlighted ASPECTS regions and an automated editable ASPECTS score for clinician review.". Read from the exact FDA decision document on 2026-11-14.

Required input
NCCT brain data for patients over 21 with known MCA/ICA occlusion, within the labeled ischemia time window.
  • Exact FDA submission
  • Checked 2026-09-19

FDA patient, indication, and image-input scope.

Output and clinician action
Editable ASPECTS score, highlighted/labelled regions, voxel-inclusion/exclusion heatmaps, affected side, report, and PACS-exportable results.
  • Exact FDA submission
  • Checked 2026-09-19

FDA output and workflow description.

Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Clinicians and physicians, with physician review and verification.
  • Exact FDA submission
  • Checked 2026-09-19

FDA clinician/physician review boundary.

Limitations
Not primary CT interpretation; not validated for non-acute-stroke pathologies, hemorrhagic transformation, hematoma, motion-degraded scans, or use outside brain ischemia within 6 hours; intended for patients over 21 and Siemens Somatom Definition scanners; not for mobile diagnostic use.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA limitations and cautions.

Evidence summary
FDA reports standalone testing on 256 NCCT scans from 8 U.S. institutions: AUC 83% (81-85), sensitivity 68% (57-72), and specificity 97% (86-98); it also reports 200 digital-phantom heatmap testing and a 54-scan/10-reader MRMC study.
  • Exact FDA submission
  • Checked 2026-09-19

Submission-reported FDA evidence summary, not an independent clinical endorsement.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA reports standalone testing on 256 NCCT scans from 8 U.S. institutions: AUC 83% (81-85), sensitivity 68% (57-72), and specificity 97% (86-98); it also reports 200 digital-phantom heatmap testing and a 54-scan/10-reader MRMC study.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Submission-reported FDA evidence summary, not an independent clinical endorsement.

Reported sensitivity
68% (57-72)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
97% (86-98)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Brainomix 360 e-ASPECTS regulatory performance study summary

  • DesignStand-alone performance and reader study (ACR AI Central category)
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K221564
  • Samplen=256
  • Sites8
  • IndependenceIndependence not established

K221564

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K221564. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: NCCT brain data for patients over 21 with known MCA/ICA occlusion, within the labeled ischemia time window.

    Scope: Exact FDA submission. FDA patient, indication, and image-input scope.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K221564: Brainomix 360 e-ASPECTS

  2. Routing

    Source context, not route validation: The exact FDA package describes connecting with DICOM-compliant devices to transfer NCCT scans from PACS for processing, sending results and images to a PACS via DICOM transfer, and compressed e-mail image previews for notification. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "Brainomix 360 e-ASPECTS can connect with other DICOM-compliant devices, for example to transfer NCCT scans from a Picture Archiving and Communication System (PACS) to Brainomix 360 e-ASPECTS software for processing." … "Results and images can be sent to a PACS via DICOM transfer and can be viewed on a PACS workstation". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA K221564: Brainomix 360 e-ASPECTS

  3. AI processing

    Source context, not route validation: The exact FDA package describes a computer platform of a standard off-the-shelf server or virtual server, with results viewable on a PACS workstation or via a web user interface on any machine within a hospital network and firewall connected to the software. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Design: Computer Standard off-the-shelf server or same Platform virtual server" … "can be viewed on a PACS workstation or via a web user interface on any machine contained and accessed within a hospital network and firewall and with a connection to the Brainomix 360° e-ASPECTS software". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K221564: Brainomix 360 e-ASPECTS

  4. Returned objects

    Source context, not route validation: Editable ASPECTS score, highlighted/labelled regions, voxel-inclusion/exclusion heatmaps, affected side, report, and PACS-exportable results.

    Scope: Exact FDA submission. FDA output and workflow description.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K221564: Brainomix 360 e-ASPECTS

  5. Viewer/worklist/report

    Unresolved route: Editable ASPECTS score, highlighted/labelled regions, voxel-inclusion/exclusion heatmaps, affected side, report, and PACS-exportable results.

    Scope: Exact FDA submission. FDA output and workflow description.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K221564: Brainomix 360 e-ASPECTS

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes a computer platform of a standard off-the-shelf server or virtual server, with results viewable on a PACS workstation or via a web user interface on any machine within a hospital network and firewall connected to the software. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Design: Computer Standard off-the-shelf server or same Platform virtual server" … "can be viewed on a PACS workstation or via a web user interface on any machine contained and accessed within a hospital network and firewall and with a connection to the Brainomix 360° e-ASPECTS software". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact FDA package describes connecting with DICOM-compliant devices to transfer NCCT scans from PACS for processing, sending results and images to a PACS via DICOM transfer, and compressed e-mail image previews for notification. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Brainomix 360 e-ASPECTS can connect with other DICOM-compliant devices, for example to transfer NCCT scans from a Picture Archiving and Communication System (PACS) to Brainomix 360 e-ASPECTS software for processing." … "Results and images can be sent to a PACS via DICOM transfer and can be viewed on a PACS workstation". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Security
Brainomix's current official FAQ describes ISO 27001, GDPR, and DPA controls for the current Brainomix 360 family; this does not establish certificate scope, expiry, deployed configuration, or exact K243294 security controls.
  • Product family
  • Checked 2026-10-25

Obtain current certificate scope, data-processing terms, hosting region, encryption, identity/access, audit, retention, and incident-response evidence for the deployed release.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Brainomix 360 e-ASPECTS; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K221564
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

FDA specifies non-contrast CT; normalized to the controlled CT/CTA catalog enum.

Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

FDA brain/ASPECTS-region scope.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-02-23
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K221564 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K221564: Brainomix 360 e-ASPECTS

    U.S. Food and Drug Administration - Published 2023-02-23 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary, deployment, integration

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Brainomix 360 e-ASPECTS model card (K221564)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Brainomix 360 official FAQ

    Brainomix Limited - Accessed 2026-09-07

    Scope: productFamily, implementationCapabilities, security, training

  8. openFDA exact recall query for K221564

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K221564 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K242123

Brainomix 360 e-CTA

Brainomix Limited

Authorized purpose: Brainomix 360 e-CTA analyzes adult CTA brain DICOM for vessel visualization and post-processing, including MCA vessel-density asymmetry, contrast/phase context, overlays, and MIP views, for trained clinical review; it is not for mobile diagnosis and its vessel-density asymmetry ratio is limited to the MCA region.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-01-06
FDA-cleared K193289

FastStroke, CT Perfusion 4D

GE Medical Systems SCS

Authorized purpose: Analyzes CT data to display head and neck vasculature and CT perfusion to generate regional blood-flow, blood-volume, mean-transit-time, and capillary-permeability images.

Modality
CT/CTA
Anatomy
Brain
Decision
2020-11-12
FDA-cleared K192962

icobrain-ctp

Icometrix NV

Authorized purpose: Analyzes and communicates dynamic CT-perfusion datasets.

Modality
CT/CTA
Anatomy
Brain
Decision
2020-02-28
FDA-cleared K181247

Vitrea CT Brain Perfusion

Vital Images, Inc.

Authorized purpose: Non-invasive post-processing for brain perfusion that calculates CBF, CBV, bolus timing/TTP, and MTT.

Modality
CT/CTA
Anatomy
Brain
Decision
2018-11-20

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history